Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates

Steven M. Ansell, Sharon A. Johnstone, Paul G. Tardi, Lily Lo, Sherwin Xie, Yu Shu, Troy O. Harasym, Natashia L. Harasym, Laura Williams, David Bermudes, Barry D. Liboiron, Walid Saad, Robert K. Prud'homme, Lawrence D. Mayer

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

A series of paclitaxel prodrugs designed for formulation in lipophilic nanoparticles are described. The hydrophobicity of paclitaxel was increased by conjugating a succession of increasingly hydrophobic lipid anchors to the drug using succinate or diglycolate cross-linkers. The prodrugs were formulated in well defined block copolymer-stabilized nanoparticles. These nanoparticles were shown to have an elimination half-life of approximately 24 h in vivo. The rate at which the prodrug was released from the nanoparticles could be controlled by adjusting the hydrophobicity of the lipid anchor, resulting in release half-lives ranging from 1 to 24 h. The diglycolate and succinate cross-linked prodrugs were 1-2 orders of magnitude less potent than paclitaxel in vitro. Nanoparticle formulations of the succinate prodrugs showed no evidence of efficacy in HT29 human colorectal tumor xenograph models. Efficacy of diglycolate prodrug nanoparticles increased as the anchor hydrophobicity increased. Long circulating diglycolate prodrug nanoparticles provided significantly enhanced therapeutic activity over commercially formulated paclitaxel at the maximum tolerated dose.

Original languageEnglish
Pages (from-to)3288-3296
Number of pages9
JournalJournal of Medicinal Chemistry
Volume51
Issue number11
DOIs
StatePublished - Jun 12 2008

Fingerprint

Prodrugs
Hydrophobicity
Paclitaxel
Hydrophobic and Hydrophilic Interactions
Nanoparticles
Succinic Acid
Anchors
Therapeutics
Lipids
Maximum Tolerated Dose
Block copolymers
Half-Life
Tumors
Colorectal Neoplasms
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. / Ansell, Steven M.; Johnstone, Sharon A.; Tardi, Paul G.; Lo, Lily; Xie, Sherwin; Shu, Yu; Harasym, Troy O.; Harasym, Natashia L.; Williams, Laura; Bermudes, David; Liboiron, Barry D.; Saad, Walid; Prud'homme, Robert K.; Mayer, Lawrence D.

In: Journal of Medicinal Chemistry, Vol. 51, No. 11, 12.06.2008, p. 3288-3296.

Research output: Contribution to journalArticle

Ansell, SM, Johnstone, SA, Tardi, PG, Lo, L, Xie, S, Shu, Y, Harasym, TO, Harasym, NL, Williams, L, Bermudes, D, Liboiron, BD, Saad, W, Prud'homme, RK & Mayer, LD 2008, 'Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates', Journal of Medicinal Chemistry, vol. 51, no. 11, pp. 3288-3296. https://doi.org/10.1021/jm800002y
Ansell, Steven M. ; Johnstone, Sharon A. ; Tardi, Paul G. ; Lo, Lily ; Xie, Sherwin ; Shu, Yu ; Harasym, Troy O. ; Harasym, Natashia L. ; Williams, Laura ; Bermudes, David ; Liboiron, Barry D. ; Saad, Walid ; Prud'homme, Robert K. ; Mayer, Lawrence D. / Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates. In: Journal of Medicinal Chemistry. 2008 ; Vol. 51, No. 11. pp. 3288-3296.
@article{7c67e321fee64a1484aefaf274f086a5,
title = "Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates",
abstract = "A series of paclitaxel prodrugs designed for formulation in lipophilic nanoparticles are described. The hydrophobicity of paclitaxel was increased by conjugating a succession of increasingly hydrophobic lipid anchors to the drug using succinate or diglycolate cross-linkers. The prodrugs were formulated in well defined block copolymer-stabilized nanoparticles. These nanoparticles were shown to have an elimination half-life of approximately 24 h in vivo. The rate at which the prodrug was released from the nanoparticles could be controlled by adjusting the hydrophobicity of the lipid anchor, resulting in release half-lives ranging from 1 to 24 h. The diglycolate and succinate cross-linked prodrugs were 1-2 orders of magnitude less potent than paclitaxel in vitro. Nanoparticle formulations of the succinate prodrugs showed no evidence of efficacy in HT29 human colorectal tumor xenograph models. Efficacy of diglycolate prodrug nanoparticles increased as the anchor hydrophobicity increased. Long circulating diglycolate prodrug nanoparticles provided significantly enhanced therapeutic activity over commercially formulated paclitaxel at the maximum tolerated dose.",
author = "Ansell, {Steven M.} and Johnstone, {Sharon A.} and Tardi, {Paul G.} and Lily Lo and Sherwin Xie and Yu Shu and Harasym, {Troy O.} and Harasym, {Natashia L.} and Laura Williams and David Bermudes and Liboiron, {Barry D.} and Walid Saad and Prud'homme, {Robert K.} and Mayer, {Lawrence D.}",
year = "2008",
month = "6",
day = "12",
doi = "10.1021/jm800002y",
language = "English",
volume = "51",
pages = "3288--3296",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates

AU - Ansell, Steven M.

AU - Johnstone, Sharon A.

AU - Tardi, Paul G.

AU - Lo, Lily

AU - Xie, Sherwin

AU - Shu, Yu

AU - Harasym, Troy O.

AU - Harasym, Natashia L.

AU - Williams, Laura

AU - Bermudes, David

AU - Liboiron, Barry D.

AU - Saad, Walid

AU - Prud'homme, Robert K.

AU - Mayer, Lawrence D.

PY - 2008/6/12

Y1 - 2008/6/12

N2 - A series of paclitaxel prodrugs designed for formulation in lipophilic nanoparticles are described. The hydrophobicity of paclitaxel was increased by conjugating a succession of increasingly hydrophobic lipid anchors to the drug using succinate or diglycolate cross-linkers. The prodrugs were formulated in well defined block copolymer-stabilized nanoparticles. These nanoparticles were shown to have an elimination half-life of approximately 24 h in vivo. The rate at which the prodrug was released from the nanoparticles could be controlled by adjusting the hydrophobicity of the lipid anchor, resulting in release half-lives ranging from 1 to 24 h. The diglycolate and succinate cross-linked prodrugs were 1-2 orders of magnitude less potent than paclitaxel in vitro. Nanoparticle formulations of the succinate prodrugs showed no evidence of efficacy in HT29 human colorectal tumor xenograph models. Efficacy of diglycolate prodrug nanoparticles increased as the anchor hydrophobicity increased. Long circulating diglycolate prodrug nanoparticles provided significantly enhanced therapeutic activity over commercially formulated paclitaxel at the maximum tolerated dose.

AB - A series of paclitaxel prodrugs designed for formulation in lipophilic nanoparticles are described. The hydrophobicity of paclitaxel was increased by conjugating a succession of increasingly hydrophobic lipid anchors to the drug using succinate or diglycolate cross-linkers. The prodrugs were formulated in well defined block copolymer-stabilized nanoparticles. These nanoparticles were shown to have an elimination half-life of approximately 24 h in vivo. The rate at which the prodrug was released from the nanoparticles could be controlled by adjusting the hydrophobicity of the lipid anchor, resulting in release half-lives ranging from 1 to 24 h. The diglycolate and succinate cross-linked prodrugs were 1-2 orders of magnitude less potent than paclitaxel in vitro. Nanoparticle formulations of the succinate prodrugs showed no evidence of efficacy in HT29 human colorectal tumor xenograph models. Efficacy of diglycolate prodrug nanoparticles increased as the anchor hydrophobicity increased. Long circulating diglycolate prodrug nanoparticles provided significantly enhanced therapeutic activity over commercially formulated paclitaxel at the maximum tolerated dose.

UR - http://www.scopus.com/inward/record.url?scp=44949198237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949198237&partnerID=8YFLogxK

U2 - 10.1021/jm800002y

DO - 10.1021/jm800002y

M3 - Article

C2 - 18465845

AN - SCOPUS:44949198237

VL - 51

SP - 3288

EP - 3296

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 11

ER -